FERMA549003
C9 Neoantigen Monoclonal Antibody (WU13-15), Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | FERMA549003-Each-of-1 | In Stock | ₹ 56,248.00 |
FERMA549003 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 56,248.00
GST (18%): ₹ 10,124.64
Total Price: ₹ 66,372.64
Antigen
C9 Neoantigen
Classification
Monoclonal
Concentration
100 μg/mL
Formulation
PBS with 0.1% BSA and 0.02% sodium azide
Host Species
Mouse
Purification Method
Protein G
Regulatory Status
RUO
Target Species
Human
Form
Liquid
Applications
Flow Cytometry, Immunocytochemistry, Immunohistochemistry (Frozen), Immunohistochemistry (Paraffin), Inhibition Assays, Western Blot
Clone
WU13-15
Conjugate
Unconjugated
Gene Alias
C9
Immunogen
The monoclonal antibody WU13-15 recognizes a neoepitope on the 61 kDa complement component C9, integrated in the terminal complement complex (TCC).
Quantity
100 μg
Primary or Secondary
Primary
Content And Storage
4° C
Isotype
IgG1
Related Products
Description
- C9 neoantigen is a target gene that is involved in the immune system's response to cancer cells
- Neoantigens are proteins that are produced by cancer cells and are not present in normal cells
- C9 neoantigen is a protein fragment that is produced when the C9 protein is broken down by enzymes in the cancer cells
- The immune system recognizes these neoantigens as foreign and mounts an attack against the cancer cells
- C9 neoantigen is being studied as a potential target for cancer immunotherapy, which involves using the patient's own immune system to fight cancer.